Quantcast

Latest photodynamic therapy Stories

2010-11-05 05:30:00

WILMINGTON, Mass., Nov. 5, 2010 /PRNewswire/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2010. Third quarter and year-to-date financial highlights: Domestic...

2010-10-26 14:33:00

WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list. For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America. Rankings are based on percentage of...

2010-10-19 16:09:49

New LED device may help advance photodynamic therapy for skin cancer Can skin cancer be treated with light? Scientists at the University of California, Irvine (UC Irvine), believe so. They're exploring new ways to image cancerous lesions using LEDs that might advance a technique for treating cancer called photodynamic therapy (PDT) -- work that they will describe at the Optical Society's (OSA) 94th annual meeting, Frontiers in Optics (FiO) 2010 at the Rochester Riverside Convention Center in...

2010-08-06 11:01:00

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(Nasdaq: DUSA) reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration (FDA) notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan(®) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple...

2010-08-03 05:30:00

WILMINGTON, Mass., Aug. 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2010. Financial highlights for the second quarter and first half of the year include: Domestic...

2010-07-28 00:06:21

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells. "This minimally invasive technique for localized prostate cancer offers the potential to destroy the cancer without making any incision or causing any potentially devastating sexual,...

2010-06-24 05:30:00

All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and...

2010-05-13 11:04:00

WILMINGTON, Mass., May 13 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, today announced that its Annual Meeting of Shareholders will be held on Thursday, July 29, 2010 at 11:00 AM at the Company's offices at 25 Upton Drive, Wilmington, MA. The Company also reported that...

2010-05-11 08:30:00

TSX Venture: QPT EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052...

2010-05-11 05:30:00

WILMINGTON, Mass., May 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010. Highlights for the first quarter include: Total product revenues were $8.7 million for...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related